Tyvaso DPI 48-64 mcg Maintenance Pack
RxNorm 2641912

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2641912 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Tyvaso DPI 48-64 mcg Maintenance Pack.

The following semantic concepts and normalized strings are associated with this clinical entity:

PSN
Tyvaso DPI 48-64 mcg Maintenance Pack
AUI:12820627
View
SY
Tyvaso DPI 48-64 mcg Maintenance Pack
AUI:12820626
View
BPCK
{112 (treprostinil 0.048 mg Inhalation Powder [Tyvaso]) / 112 (treprostinil 0.064 mg Inhalation Powder [Tyvaso]) } Pack [Tyvaso 48-64 mcg Maintenance Pack]
AUI:12820625
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PSNPrescribable

Prescribable Name (PSN):
Tyvaso DPI 48-64 mcg Maintenance Pack
(Atom ID: 12820627)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Tyvaso DPI 48-64 MCG Maintenance Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2641912
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12820627
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2641912
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SYPrescribable

Synonym (SY):
Tyvaso DPI 48-64 mcg Maintenance Pack
(Atom ID: 12820626)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Tyvaso DPI 48-64 MCG Maintenance Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2641912
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12820626
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2641912
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
BPCKPrescribable

Brand Name Pack (BPCK):
{112 (treprostinil 0.048 mg Inhalation Powder [Tyvaso]) / 112 (treprostinil 0.064 mg Inhalation Powder [Tyvaso]) } Pack [Tyvaso 48-64 mcg Maintenance Pack]
(Atom ID: 12820625)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{112 (treprostinil 0.048 MG Inhalation Powder [Tyvaso]) / 112 (treprostinil 0.064 MG Inhalation Powder [Tyvaso]) } Pack [Tyvaso 48-64 MCG Maintenance Pack]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2641912
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12820625
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
BPCK
Brand Name Pack ({# (Ingredient Strength Dose Form) / # (Ingredient Strength Dose Form)} Pack [Brand Name])
Source Code
2641912
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans

Patient Education

Treprostinil Oral Inhalation


Treprostinil oral inhalation is used to treat certain kinds of pulmonary arterial hypertension (PAH; high blood pressure in the vessels carrying blood to the lungs, causing shortness of breath, dizziness, and tiredness). Treprostinil oral inhalation is also used to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD; high blood pressure in the lungs resulting from a lung disease that involves inflammation and scarring of the lungs). Treprostinil may improve the ability to exercise and slow the worsening of symptoms in patients with PAH and PH-ILD. Treprostinil is in a class of medications called vasodilators and platelet-aggregation inhibitors. It works by relaxing the blood vessels, including those in the lungs, and improving blood flow.
[Learn More]


* Please review the disclaimer below.